Earnings History Data for Recro Pharma, Inc. (REPH) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Recro Pharma, Inc.
Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 01-03-2022 | AH | 4:05 PM ET (Mar 1) |
REPH | Recro Pharma, Inc. | 76.59 | -0.04 | -0.07 | -0.48 | Recro Pharma GAAP EPS of -$0.04 beats by $0.03, revenue of $22.3M beats by $0.89M [3/1/2022 4:13 PM] |
1.78 | 0.10 (5.95%) |
1.75 | 0.07 (4.16%) |
1.38 - 4.01 | 237,882 | 80,000 | 600 | |
| 09-11-2021 | AH | 4:05 PM ET (Nov 9) |
REPH | Recro Pharma, Inc. | 86.24 | -0.07 | -0.05 | -0.09 | Recro Pharma EPS in-line, beats on revenue [11/9/2021 4:42 PM] |
1.70 | -0.18 (-9.57%) |
1.86 | -0.02 (-1.06%) |
1.66 - 5.29 | 1,987,225 | 250,000 | 5,005 | |
| 09-08-2021 | AH | 4:05 PM ET (Aug 9) |
REPH | Recro Pharma, Inc. | 85.77 | -0.06 | 0.00 | -0.25 | Recro Pharma EPS beats by $0.12, beats on revenue [8/9/2021 4:18 PM] |
2.05 | 0.09 (4.59%) |
2.00 | 0.04 (2.04%) |
1.49 - 5.29 | 461,382 | 220,000 | 904 | |
|
||||||||||||||||||
| 06-05-2021 | AH | 4:05 PM ET (May 6) |
REPH | Recro Pharma, Inc. | 80.32 | -0.23 | 0.00 | -0.33 | Recro Pharma EPS beats by $0.03, beats on revenue [5/6/2021 4:37 PM] |
2.92 | 0.41 (16.33%) |
2.50 | -0.01 (-0.40%) |
1.49 - 9.19 | 1,017,656 | 320,000 | 201 | |
| 26-02-2021 | PM | 7:00 AM ET (Feb 26) |
REPH | Recro Pharma, Inc. | 114.91 | -0.48 | 0.00 | 0.00 | Recro Pharma EPS misses by $0.22, misses on revenue [2/26/2021 7:07 AM] |
3.42 | -1.49 (-30.35%) |
3.98 | -0.93 (-18.94%) |
1.49 - 15.99 | 3,083,587 | 707,140 | 96,103 | |
| 09-11-2020 | PM | 7:00 AM ET (Nov 9) |
REPH | Recro Pharma, Inc. | 37.12 | -0.09 | -0.21 | -0.19 | Recro Pharma EPS beats by $0.11, beats on revenue [11/9/2020 7:07 AM] |
2.00 | 0.40 (25.00%) |
1.75 | 0.15 (9.38%) |
1.49 - 19.21 | 613,833 | 260,290 | 40,381 | |
|
|
||||||||||||||||||
| 10-08-2020 | PM | 7:00 AM ET (Aug 10) |
REPH | Recro Pharma, Inc. | 96.86 | -0.25 | -0.20 | -0.13 | Recro Pharma EPS misses by $0.09, misses on revenue [8/10/2020 7:03 AM] |
3.34 | -1.06 (-24.10%) |
3.69 | -0.71 (-16.14%) |
3.13 - 19.21 | 1,660,156 | 217,533 | 43,243 | |
|
|
||||||||||||||||||